Ketoprofen Lysine Salt — Competitive Intelligence Brief

Ketoprofen Lysine Salt (Ketoprofen Lysine Salt) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management / Rheumatology Small molecule

Target snapshot

Ketoprofen Lysine Salt (Ketoprofen Lysine Salt) — Dompé Farmaceutici S.p.A. Ketoprofen lysine salt is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketoprofen Lysine Salt TARGET	Ketoprofen Lysine Salt	Dompé Farmaceutici S.p.A	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
ACULAR	ACULAR	University of South Alabama	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Metamizole and Ibuprofen	Metamizole and Ibuprofen	University Hospital, Basel, Switzerland	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	Cyclooxygenase (COX-1 and COX-2)
ketorolac tromethamine 0.4%	ketorolac tromethamine 0.4%	Clinica Oftamologica Zona Sul	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Cefazolin and indomethacin	Cefazolin and indomethacin	Thomas Jefferson University	marketed	Beta-lactam antibiotic + NSAID combination	Bacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin)
Loxoprofen sodium hydrogel patch	Loxoprofen sodium hydrogel patch	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class